INS and metabolic dysfunction-associated steatotic liver disease: Instead, the IPFD model ranked the aromatic amino acid tyrosine, whose presence has been an established biomarker for the exacerbation of insulin dysregulation in patients with non-alcoholic fatty liver disease (NAFLD) and diabetic nephropathy (73–76).